ABSTRACT

Since the last edition of this book, major advances have been made in our understanding of key pathways that control tumor progression. This has led to the development of new anticancer agents that have the ability to block the activity of proteins involved in neoplastic cell development and proliferation. Targeted Therapies in Oncology, Second Edi

chapter 3|30 pages

HER2 Inhibition and Clinical Achievements

chapter 5|12 pages

BRAF and MEK Inhibitors

chapter 6|30 pages

KIT and KIT Inhibitors

chapter 8|18 pages

Anaplastic Lymphoma Kinase

chapter 9|26 pages

MET Inhibitors

chapter 10|18 pages

Targeting Stem Cells

chapter 12|30 pages

Targeting Apoptosis Pathways

chapter 13|32 pages

Targeting Angiogenesis

chapter 14|10 pages

Antivascular Agents

chapter 18|22 pages

Compounds Targeting Androgen Pathways

chapter 20|22 pages

Inhibitors Targeting Mitosis